View as Webpage

Claudin 18.2, An Attractive Target for Therapeutics 

Claudin 18.2, which is upregulated and mislocalized in cancer cells, has been suggested as a therapeutic target. Currently, there are several targeted drugs are in clinical trials and have shown promising results.

Its clinical trials in patients with advanced cancer have yielded positive results with few high-grade adverse events. Following the success of zolbetuximab in treating cancer illustrates the importance of characterizing these proteins to optimize drug discovery.

Mechanisms of Action of zolbetuximab on cancer cells

High quality of Claudin 18.2 verified by Alto™ Digital platform

ACROBiosystems' Claudin 18.2 protein can be characterized successfully through SPR verification of Alto™ digital platform, with kinetic parameters are similar to those determined by traditional SPR with lowered sample requirements by up to 200X.

>>Explore More

To receive the latest industry news and updates from ACROBiosystems,

visit our website & follow us on our social media!